Fundraising Fox

Renovo Rx

NASDAQ: RNXT

Mountain View, US · Delaware corporation · 1 known investors

Find your way into Renovo Rx

19 people in our graph share verified history with the Renovo Rx team — schools, employers, funds. One of them is your warm intro.

Douglas Crawfordunlockedknows Ramtin Agah · together at University of California, San Francisco (overlapped)
×9knows the team · via University of California, San Francisco
×2knows the team · via Renovo Rx

RenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.

BiotechHealthtechMedical Devices

Founders & leadership

RARamtin Agah
Ramtin AgahinFounder · Chief Medical OfficerRamtin Agah is a physician with background in medical devices, oncology, and healthcare information technology who trained at Cleveland Clinic and UCSF. He is Executive Officer of RenovoRx, which develops targeted oncology therapies and the RenovoCath, an FDA-cleared intra-arterial chemotherapy delivery device.
SRShaun R. Bagai
Shaun R. BagaiinCEO
LGLeesa Gentry
Leesa GentryinChief Clinical Officer
MVMark Voll
Mark VollinChief Financial Officer
KNKamran Najmabadi
Kamran NajmabadiinFounder

Board

KH
Klaus HambuechenBoard director
KA
Kirsten Angela MacfarlaneBoard director
LJ
Laurence J. MartonBoard director
US
Una S. RyanBoard director
RJ
Robert J. SpiegelBoard director

Investors · 1

AstiaSilicon Valley

Reported raises · per SEC filings

Form D private placements

$37.7M disclosed across 5 rounds · 2015–2026

▶$10MraisedApr 2026 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shaun R. BagaiExecutive Officer, Director
  • Kirsten Angela MacfarlaneDirector
  • Laurence J. MartonDirector
  • Leesa GentryExecutive Officer
  • Mark VollExecutive Officer
  • Una S. RyanDirector
  • Robert J. SpiegelDirector
  • Ramtin AgahExecutive Officer
Offering amount
$10M
Amount sold
$10M
Minimum investment
$10K
Sales commissions
$550K
Placement agents
T.R. WINSTON & COMPANY, LLC
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.1MraisedApr 2024 · 172 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kirsten Angela MacfarlaneDirector
  • Ramtin AgahExecutive Officer, Director
  • Shaun R. BagaiExecutive Officer, Director
  • Laurence J. MartonDirector
  • Leesa GentryExecutive Officer
  • Ronald B. KocakExecutive Officer
  • Robert SpiegelDirector
  • Una S. RyanDirector
Offering amount
$15M
Amount sold
$11.1M
Sales commissions
$1.3M
Placement agents
Newbridge Securities Corporation
First sale
Apr 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedFeb 2024 · 92 investors · Other Health Care
Rule 506(c)
Officers, directors & promoters on the filing
  • Laurence J. MartonDirector
  • Una S. RyanDirector
  • Robert SpiegelDirector
  • Ramtin AgahExecutive Officer, Director
  • Shaun R. BagaiExecutive Officer, Director
  • Angela Gill NelmsExecutive Officer
  • Kirsten Angela MacfarlaneDirector
  • Ron KocakExecutive Officer
Offering amount
$15M
Amount sold
$6.1M
Minimum investment
$10K
Sales commissions
$508K
Placement agents
PAULSON INVESTMENT COMPANY LLC
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$8.3MraisedJun 2018 · 21 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ramtin AgahExecutive Officer, Director
  • Laurence J. MartonDirector
  • Una S. RyanDirector
  • Shaun R. BagaiExecutive Officer, Director
  • Kamran NajmabadiExecutive Officer
Offering amount
$13.7M
Amount sold
$8.3M
First sale
Apr 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.1MraisedJan 2016 · 18 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Shaun R. BagaiExecutive Officer, Director
  • Laurence J. MartonDirector
  • Klaus HambuechenDirector
  • Ramtin AgahExecutive Officer, Director
  • Una S. RyanDirector
  • Kamran NajmabadiExecutive Officer
Offering amount
$2.1M
Amount sold
$2.1M
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld48 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Renovo Rx for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Renovo Rx do?
RenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Who founded Renovo Rx?
Renovo Rx was founded by Ramtin Agah.
Who are Renovo Rx's investors?
Renovo Rx's investors include Astia.
How much funding has Renovo Rx raised?
Renovo Rx has disclosed $37.7M raised across 5 rounds.
Where is Renovo Rx headquartered?
Renovo Rx is headquartered in Mountain View, US.